With 0.77 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.81 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $10.51 whereas the lowest price it dropped to was $9.94. The 52-week range on CDNA shows that it touched its highest point at $12.93 and its lowest point at $4.80 during that stretch. It currently has a 1-year price target of $13.00. Beta for the stock currently stands at 1.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDNA was up-trending over the past week, with a rise of 35.05%, but this was up by 9.97% over a month. Three-month performance surged to 16.44% while six-month performance rose 66.09%. The stock gained 24.91% in the past year, while it has lost -12.67% so far this year. A look at the trailing 12-month EPS for CDNA yields -3.55 with Next year EPS estimates of -1.32. For the next quarter, that number is -0.47. This implies an EPS growth rate of 55.36% for this year and 16.67% for next year. EPS is expected to grow by 20.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.96%.
Float and Shares Shorts:
At present, 51.50 million CDNA shares are outstanding with a float of 48.91 million shares on hand for trading. On 2024-04-15, short shares totaled 4.69 million, which was 906.0001 higher than short shares on 1710460800. In addition to Mr. Abhishek Jain as the firm’s CFO & Principal Accounting Officer, Dr. Peter Maag Ph.D. serves as its Executive Director.
Institutional Ownership:
Through their ownership of 0.96429 of CDNA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, CDNA reported revenue of $65569000.0 and operating income of -$24860000.0. The EBITDA in the recently reported quarter was $77961000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDNA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
